Endomyocardial expression of SDF-1 predicts mortality in patients with suspected myocarditis
Tóm tắt
Risk stratification in patients with suspected myocarditis is pivotal for optimizing therapy. Stromal cell-derived factor 1 (SDF-1) is an inflammatory chemokine expressed in the inflamed and failing myocardium. Therefore, we aimed to investigate whether endomyocardial expression of SDF-1 identifies high-risk patients with suspected myocarditis. We prospectively enrolled 174 patients with non-ischemic HF who underwent endomyocardial biopsy for suspected myocarditis. Biopsies were analyzed using established histopathological and immunohistological criteria together with SDF-1 staining. SDF-1 was significantly enhanced in patients with inflammatory cardiomyopathy (65.4 % positive biopsies) as compared to patients with non-inflammatory cardiomyopathy (19.1 %, p < 0.001). SDF-1 expression levels correlated significantly with the degree of myocardial fibrosis (correlation coefficient r = 0.196; p = 0.010) since patients with severe myocardial fibrosis displayed high myocardial SDF-1 expression. During a mean follow-up of 27.5 months, 20 patients (11.5 %) died. The 4-year mortality rate was 26.0 % among the 92 SDF-1-positive patients vs. 9.5 % among the 82 SDF-1-negative patients (p = 0.001). On multivariable analysis which considered clinical (NYHA functional class, left ventricular ejection fraction), laboratory (brain natriuretic peptide, troponin I) and biopsy staining, SDF-1 was the strongest independent predictor of mortality (hazard ratio 6.1; 95 % confidence interval 1.4–27.5; p = 0.018). Subgroup analysis revealed SDF-1 as a predictor of mortality in both patients with inflammatory and non-inflammatory cardiomyopathy. Endomyocardial expression of SDF-1 is enhanced in inflammatory cardiomyopathy, positively correlates with myocardial fibrosis and identifies high-risk patients with suspected myocarditis.
Tài liệu tham khảo
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart Association, Council on Clinical Cardiology, Heart Failure and Transplantation Committee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, Council on Epidemiology and Prevention (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807–1816. doi:10.1161/CIRCULATIONAHA.106.174287
Elamm C, Fairweather D, Cooper LT (2012) Pathogenesis and diagnosis of myocarditis. Heart 98:835–840. doi:10.1136/heartjnl-2012-301686
Chandra D, Kar B, Idelchik G, Simpson L, Loyalka P, Gregoric ID, Delgado RM 3rd, Frazier OH (2007) Usefulness of percutaneous left ventricular assist device as a bridge to recovery from myocarditis. Am J Cardiol 99:1755–1756. doi:10.1016/j.amjcard.2007.01.067
Cooper LT Jr (2009) Myocarditis. N Engl J Med 360:1526–1538. doi:10.1056/NEJMra0800028
Yoshizawa S, Kato TS, Mancini D, Marboe CC (2013) Outcome of patients having heart transplantation for lymphocytic myocarditis. Am J Cardiol 112:405–410. doi:10.1016/j.amjcard.2013.03.042
Ahmed A, Perry GJ, Fleg JL, Love TE, Goff DC Jr, Kitzman DW (2006) Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis. Am Heart J 152:956–966. doi:10.1016/j.ahj.2006.06.020
Michels VV, Driscoll DJ, Miller FA, Olson TM, Atkinson EJ, Olswold CL, Schaid DJ (2003) Progression of familial and non-familial dilated cardiomyopathy: long term follow up. Heart 89:757–761
Ukena C, Kindermann M, Mahfoud F, Geisel J, Lepper PM, Kandolf R, Bohm M, Kindermann I (2014) Diagnostic and prognostic validity of different biomarkers in patients with suspected myocarditis. Clin Res Cardiol 103:743–751. doi:10.1007/s00392-014-0709-z
Miller WL, Hartman KA, Burritt MF, Burnett JC Jr, Jaffe AS (2007) Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. Clin Cardiol 30:245–250. doi:10.1002/clc.20075
Nagarajan V, Hernandez AV, Tang WH (2012) Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart 98:1778–1786. doi:10.1136/heartjnl-2012-301779
Frioes F, Lourenco P, Laszczynska O, Almeida PB, Guimaraes JT, Januzzi JL, Azevedo A, Bettencourt P (2015) Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol. doi:10.1007/s00392-015-0811-x
Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102:103–110. doi:10.1007/s00392-012-0500-y
Volz HC, Laohachewin D, Schellberg D, Wienbrandt AR, Nelles M, Zugck C, Kaya Z, Katus HA, Andrassy M (2012) HMGB1 is an independent predictor of death and heart transplantation in heart failure. Clin Res Cardiol 101:427–435. doi:10.1007/s00392-011-0409-x
Fujita B, Franz M, Goebel B, Fritzenwanger M, Figulla HR, Kuethe F, Ferrari M, Jung C (2012) Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy. Clin Res Cardiol 101:701–707. doi:10.1007/s00392-012-0447-z
Kindermann I, Kindermann M, Kandolf R, Klingel K, Bultmann B, Muller T, Lindinger A, Bohm M (2008) Predictors of outcome in patients with suspected myocarditis. Circulation 118:639–648. doi:10.1161/CIRCULATIONAHA.108.769489
Escher F, Vetter R, Kuhl U, Westermann D, Schultheiss HP, Tschope C (2011) Fractalkine in human inflammatory cardiomyopathy. Heart 97:733–739. doi:10.1136/hrt.2010.205716
Penn MS, Mendelsohn FO, Schaer GL, Sherman W, Farr M, Pastore J, Rouy D, Clemens R, Aras R, Losordo DW (2013) An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res 112:816–825. doi:10.1161/CIRCRESAHA.111.300440
Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS (2003) Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362:697–703. doi:10.1016/S0140-6736(03)14232-8
Bromage DI, Davidson SM, Yellon DM (2014) Stromal derived factor 1alpha: a chemokine that delivers a two-pronged defence of the myocardium. Pharmacol Ther 143:305–315. doi:10.1016/j.pharmthera.2014.03.009
Rath D, Chatterjee M, Borst O, Muller K, Stellos K, Mack AF, Bongartz A, Bigalke B, Langer H, Schwab M, Gawaz M, Geisler T (2014) Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery. Eur Heart J 35:386–394. doi:10.1093/eurheartj/eht448
Wurster T, Tegtmeyer R, Borst O, Rath D, Geisler T, Gawaz M, Bigalke B (2014) Platelet expression of stromal cell-derived factor-1 is associated with the degree of valvular aortic stenosis. PLoS One 9:e97405. doi:10.1371/journal.pone.0097405
Ziegler M, Elvers M, Baumer Y, Leder C, Ochmann C, Schonberger T, Jurgens T, Geisler T, Schlosshauer B, Lunov O, Engelhardt S, Simmet T, Gawaz M (2012) The bispecific SDF1-GPVI fusion protein preserves myocardial function after transient ischemia in mice. Circulation 125:685–696. doi:10.1161/CIRCULATIONAHA.111.070508
Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858–864. doi:10.1038/nm1075
Saxena A, Fish JE, White MD, Yu S, Smyth JW, Shaw RM, DiMaio JM, Srivastava D (2008) Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 117:2224–2231. doi:10.1161/CIRCULATIONAHA.107.694992
Stellos K, Langer H, Daub K, Schoenberger T, Gauss A, Geisler T, Bigalke B, Mueller I, Schumm M, Schaefer I, Seizer P, Kraemer BF, Siegel-Axel D, May AE, Lindemann S, Gawaz M (2008) Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 117:206–215. doi:10.1161/CIRCULATIONAHA.107.714691
Geisler T, Fekecs L, Wurster T, Chiribiri A, Schuster A, Nagel E, Miller S, Gawaz M, Stellos K, Bigalke B (2012) Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI. Eur J Radiol 81:e486–e490. doi:10.1016/j.ejrad.2011.06.019
Stellos K, Bigalke B, Langer H, Geisler T, Schad A, Kogel A, Pfaff F, Stakos D, Seizer P, Muller I, Htun P, Lindemann S, Gawaz M (2009) Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur Heart J 30:584–593. doi:10.1093/eurheartj/ehn566
Subramanian S, Liu C, Aviv A, Ho JE, Courchesne P, Muntendam P, Larson MG, Cheng S, Wang TJ, Mehta NN, Levy D (2014) Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arterioscler Thromb Vasc Biol 34:2100–2105. doi:10.1161/ATVBAHA.114.303579
Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R, American Heart Association, American College of Cardiology, European Society of Cardiology (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116:2216–2233. doi:10.1161/CIRCULATIONAHA.107.186093
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, ESC Committee for Practice Guidelines (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869. doi:10.1093/eurjhf/hfs105
Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R (2004) Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol 193:101–107. doi:10.1007/s00430-003-0190-1
Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U (2006) Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114:1581–1590. doi:10.1161/CIRCULATIONAHA.105.606509
Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93:841–842
Kawai C (1999) From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99:1091–1100
Rutschow S, Li J, Schultheiss HP, Pauschinger M (2006) Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res 69:646–656. doi:10.1016/j.cardiores.2005.12.009
Zuern CS, Muller KA, Seizer P, Geisler T, Banya W, Klingel K, Kandolf R, Bauer A, Gawaz M, May AE (2013) Cyclophilin A predicts clinical outcome in patients with congestive heart failure undergoing endomyocardial biopsy. Eur J Heart Fail 15:176–184. doi:10.1093/eurjhf/hfs185
Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C (1986) Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 55:575–581
Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76:378–382
Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184:1101–1109
Borst O, Schaub M, Walker B, Sauter M, Muenzer P, Gramlich M, Mueller K, Geisler T, Lang F, Klingel K, Kandolf R, Bigalke B, Gawaz M, Zuern CS (2014) CXCL16 is a novel diagnostic marker and predictor of mortality in inflammatory cardiomyopathy and heart failure. Int J Cardiol 176:896–903. doi:10.1016/j.ijcard.2014.08.033
Fuse K, Kodama M, Hanawa H, Okura Y, Ito M, Shiono T, Maruyama S, Hirono S, Kato K, Watanabe K, Aizawa Y (2001) Enhanced expression and production of monocyte chemoattractant protein-1 in myocarditis. Clin Exp Immunol 124:346–352
Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva TI, Borodovsky A, Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C, Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M (2014) Silencing of CCR2 in myocarditis. Eur Heart J. doi:10.1093/eurheartj/ehu225
Hohensinner PJ, Rychli K, Zorn G, Hulsmann M, Berger R, Mortl D, Richter B, Huber K, Wojta J, Pacher R, Niessner A (2010) Macrophage-modulating cytokines predict adverse outcome in heart failure. Thromb Haemost 103:435–441. doi:10.1160/TH09-06-0399
Goser S, Ottl R, Brodner A, Dengler TJ, Torzewski J, Egashira K, Rose NR, Katus HA, Kaya Z (2005) Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 112:3400–3407. doi:10.1161/CIRCULATIONAHA.105.572396
Frangogiannis NG (2011) The stromal cell-derived factor-1/CXCR4 axis in cardiac injury and repair. J Am Coll Cardiol 58:2424–2426. doi:10.1016/j.jacc.2011.08.031
Liehn EA, Tuchscheerer N, Kanzler I, Drechsler M, Fraemohs L, Schuh A, Koenen RR, Zander S, Soehnlein O, Hristov M, Grigorescu G, Urs AO, Leabu M, Bucur I, Merx MW, Zernecke A, Ehling J, Gremse F, Lammers T, Kiessling F, Bernhagen J, Schober A, Weber C (2011) Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol 58:2415–2423. doi:10.1016/j.jacc.2011.08.033
Chu PY, Mariani J, Finch S, McMullen JR, Sadoshima J, Marshall T, Kaye DM (2010) Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. Am J Pathol 176:1735–1742. doi:10.2353/ajpath.2010.090574
Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L (2001) Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37:183–188
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (1999). Lancet 353:2001–2007
Van Linthout S, Miteva K, Tschope C (2014) Crosstalk between fibroblasts and inflammatory cells. Cardiovasc Res 102:258–269. doi:10.1093/cvr/cvu062
Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschope C (2011) Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4:44–52. doi:10.1161/CIRCHEARTFAILURE.109.931451